Bicycle therapeutics announces continued clinical progress and updates to management team

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced continued progress in its ongoing phase i/ii clinical trials of bt8009, bt5528 and bt7480. “last quarter, we reported interim clinical results from ongoing trials of two of our bicycle toxin conjugates, bt8009 and bt5528, demonstrating preliminary
BCYC Ratings Summary
BCYC Quant Ranking